Epidemiological and Clinical Data in Low and Intermediate Risk Neuroblastoma: A Single Institution Experience and Survival Outcomes in Jerusalem

Asian Pacific Journal of Cancer Care

article

Ala H Sbeih¹  Khadra Salami²  Fortunato Morabito³  Hani Saleh⁵ 

[1] Al-Quds University School of medicine;Augusta Victoria Hospital;Biotechnological Research Unit, Provincial Health Authority of Cosenza;Department of Hematology and Bone Marrow Transplant Unit, Augusta Victoria Hospital;Department of Paediatric Hematology/oncology, Augusta Victoria Hospital;Department of Paediatrics at Al-Quds University School of Medicine

关键词: Neuroblastoma;    risk stratification;    survival;   

DOI  :  10.31557/apjcc.2020.5.3.139-144

学科分类：内科医学

来源: West Asia Organization for Cancer Prevention

【 摘 要 】

Objective: The aim of this study is to evaluate survival outcomes in neuroblastoma patients referred to Augusta Victoria hospital, Jerusalem between 2009 and 2018. Methods: This is a retrospective study of clinical and epidemiological data evaluating 34 low and intermediate risk neuroblastoma patients treated at a paediatric hematology/oncology center. Information of demographic, treatment modalities, and survival outcome were abstracted from patients medical records. Results: Diagnosing neuroblastoma is challenging due to its wide range of signs and symptoms. In this study, 34 patients were included, with a male to female ratio of 1:26 :1.0. The most common location of the tumor is the abdomen followed by the mediastinal region. Forthy one percent of the cases presented with metastasis, mainly to the liver (20%), bone marrow (15%), and the lymph nodes (6%). Overall survival for Low risk neuroblastoma is 100% while the Intermediate risk neuroblastoma had a 93.1% chance of survival. Conclusion: The outcome and prognosis of low risk and intermediate risk Neuroblastoma is excellent as it is seen in developed countries. More attention is needed for early detection and early treatment could improve survival.

【 授权许可】

CC BY